Myostatin is a negative regulator of skeletal muscle and BMS-986089 was developed as a potential treatment for skeletal muscle diseases such as Duchenne’s muscular dystrophy (DMD) (Madireddi et al., 2016). This evidence concerns the gene MSTN and Duchenne muscular dystrophy.